ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease


You May Also Like

Immuron Commences US Non-Deal Institutional Investor Roadshow

MELBOURNE, Australia, March 12, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited ...

Five Prime Welcomes Garry Nicholson to Board of Directors

SOUTH SAN FRANCISCO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...